Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Eli Lilly and Company
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
University of California, Davis
Replimune Inc.
City of Hope Medical Center
Carevive Systems, Inc.
University of Pennsylvania
M.D. Anderson Cancer Center
Seagen Inc.
Fred Hutchinson Cancer Center
AgonOx, Inc.
Eli Lilly and Company
Novartis
Inhibrx Biosciences, Inc
Varian, a Siemens Healthineers Company
Complement Theory Inc.
City of Hope Medical Center
University Health Network, Toronto
National Cancer Institute (NCI)
City of Hope Medical Center
AstraZeneca
M.D. Anderson Cancer Center
Eli Lilly and Company
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
Jonsson Comprehensive Cancer Center
Milton S. Hershey Medical Center
Compugen Ltd
M.D. Anderson Cancer Center
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University of Colorado, Denver
NextCure, Inc.
Actuate Therapeutics Inc.
Revolution Medicines, Inc.
Baltimore VA Medical Center
Comprehensive Support Project for Oncology Research